Sector News

Why didn’t J&J buy Imbruvica partner Pharmacyclics? It wants hot drugs cheap, CEO says

April 7, 2015
Life sciences
Why didn’t Johnson & Johnson buy Pharmacyclics? Good question–and one The Wall Street Journal posed to CEO Alex Gorsky in a recent interview in Tokyo.
 
Recall that J&J is Pharmacyclics’ partner on the blood cancer drug Imbruvica, a fast-growing therapy in a hot field. It’s a partnership that J&J struck years ago, at a cost of some $975 million, plus a split of eventual profits. Last month, AbbVie agreed to buy Pharmacyclics–including its share of Imbruvica and some pipeline meds–for $21 billion.
 
The price stunned many analysts at the time, and Gorsky used the familiar words “thoughtful” and “disciplined” in answering the WSJ’s question. The vast majority of J&J’s acquisitions over the past 10 years–more than 100 in all–have been under $1 billion, the CEO said.
 
“Most of our investments tend to be early-on, smaller, midsize,” Gorsky told the Journal. “Occasionally we’ll go big as we did when we went after Synthes not too long ago.
 
“But in the pharma space, identifying another Zytiga, identifying the next Imbruvica is something that we’re very interested in.”
 
In other words, buy low, sell high. In biopharma, that means risk–there’s no guarantee, of course, that pipeline drugs will actually pay off as hoped–but it also means less of a write down if expectations aren’t met down the road. And J&J’s team has a strong track record of picking winners. Zytiga, for instance, is the prostate cancer pill that J&J acquired with Cougar Biotech in 2009 for $1 billion. Approved in 2011, Zytiga brought in $2.25 billion for the company last year, partly in thanks to an aggressive development program that quickly put Zytiga on the front lines of prostate cancer treatment.
 
J&J was rumored to be among the final bidders for Pharmacyclics. According to a recent securities filing, AbbVie outbid the other potential buyers by $11.25 per share in the last round, or about $1 billion. But one of those last-round bids came from a so-called Party A, the first company approached about a potential deal, the one said to be J&J.
 
Party A’s first offer was $225 per share in cash and stock, not much higher than its trading price at the time, what with rumors circulating about a merger. AbbVie’s offering in that round was $250 per share in cash and stock, with another bidder–Party B–in the middle at $240 per share. Party A’s second bid was $250 per share–but it was all cash, a structure Pharmacyclics had specifically said it didn’t want. All but guaranteed to be a nonstarter. Party B, also $250 per share, but in with stock as 42.5% of the deal. AbbVie’s? Cash and stock worth $261.25 per share.
 
By Tracy Staton
 

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]